Inflammatory Bowel Disease (IBD): Symptoms, Treatment & When to Seek Care

Inflammatory bowel disease describes a group of relapsing–remitting, immune-mediated inflammatory disorders of the gastrointestinal tract. The two principal phenotypes—Crohn’s disease and ulcerative colitis—share an exaggerated mucosal immune response to luminal antigens in genetically susceptible hosts, but differ in distribution, depth and behaviour. Crohn’s disease can affect any segment from mouth to anus, classically as patchy transmural inflammation with skip lesions, fistulae and strictures; ulcerative colitis is confined to the colon, starting at the rectum and extending proximally as continuous mucosal inflammation. A small subgroup with colitis-only disease that does not fit either pattern is described as IBD-unclassified pending definitive features.

The pathophysiology hinges on three interacting layers: a dysregulated innate and adaptive mucosal immune response, a disturbed gut microbiota, and an environmental trigger landing on a permissive genetic background. More than 240 IBD-susceptibility loci have been identified—NOD2 variants in particular for ileal Crohn’s—but no single gene explains the disease, and concordance even between identical twins is incomplete. The practical implication is that treatment dampens the immune response across multiple checkpoints rather than correcting a single causal lesion.

Both diseases are classified by anatomical extent (Montreal classification) and disease activity. The framework matters because it drives the choice of topical vs systemic therapy and the threshold for advanced agents.

↔On a small screen, swipe or scroll sideways to see the full table.

Endoscopic severity (Mayo endoscopic score for UC, SES-CD for Crohn’s) is the deeper currency: a normal-feeling patient with persistent endoscopic inflammation is at higher risk of relapse, hospitalisation and colectomy, which is why current ACG and BSG guidance frame the goal of treatment as endoscopic improvement alongside symptom control.

Symptoms hinge on disease distribution. Ulcerative colitis tends to present with blood in stool, urgency, tenesmus and crampy left-iliac-fossa pain that eases after defecation; the more proximal the disease, the more dominant the diarrhoea over rectal bleeding. Crohn’s disease is a chameleon—right-iliac-fossa pain mimicking appendicitis in ileal disease, watery diarrhoea and weight loss in colonic disease, perianal pain or discharge in fistulating disease, and oral aphthous ulceration or upper-GI symptoms in pan-enteric disease.

Patterns that change urgency

• Six or more bloody stools per day with a fever, tachycardia or anaemia—Truelove–Witts severe colitis until proven otherwise.
• Sudden, sharp abdominal pain with peritonism—exclude perforation or abscess before pushing immunosuppression.
• Unexplained weight loss >10% over 3–6 months, particularly in adolescents—drives faltering growth and surgical risk in Crohn’s.
• New joint pain, eye pain, or skin lesions on a background of GI symptoms—may be an extra-intestinal flare needing parallel specialist input.

Background and atypical presentations

Older patients (the second incidence peak after 50) often present with isolated diarrhoea, weight loss or iron-deficiency anaemia and minimal pain; do not anchor on benign aetiologies if calprotectin is raised. Children and teenagers can present with isolated short stature, delayed puberty or unexplained anaemia before any GI complaint surfaces. Travellers, recently-treated antibiotic users and immunocompromised patients can have a near-identical clinical picture from infection or drug-induced colitis—keep a parallel differential live until microbiology returns.

IBD is a multifactorial disease; the pathophysiology is best summarised as “genes load the gun, environment and microbiome pull the trigger.” Recognising the modifiable layer is what separates patient education from boilerplate.

Risk profile

• Family history—first-degree relatives carry roughly a 4–8 fold increased risk; concordance is highest in monozygotic twins for Crohn’s.
• Smoking—increases incidence and severity of Crohn’s disease but, paradoxically, is associated with milder UC; smoking cessation improves Crohn’s outcomes regardless.
• NSAIDs—a recognised flare trigger in established disease; consider acetaminophen or short-course opioids for analgesia where appropriate.
• Recent gastrointestinal infection or antibiotic course—both can unmask incident IBD or precipitate a flare; document in the history.
• Geography and ancestry—the highest incidence remains in Northern Europe, North America and Oceania, with rising incidence across newly industrialised regions; Ashkenazi Jewish ancestry confers particularly high background risk.
• Westernised dietary patterns—ultra-processed food intake and low fibre are associated with higher incidence in cohort studies; this is contextual rather than a single causal nutrient.
• Appendicectomy at a young age—associated with reduced UC risk but slightly higher Crohn’s risk in some cohorts; useful background, not actionable.

Clinical assessment

Take a structured GI history covering stool frequency, blood/mucus, urgency and tenesmus, nocturnal symptoms, weight change, oral and perianal symptoms, family history, smoking status, recent travel, antibiotics, NSAIDs and contraception. Examine for fever, tachycardia, weight, conjunctival pallor, oral ulcers, abdominal tenderness and any palpable mass; do not skip the perianal inspection in suspected Crohn’s. Abdominal assessment at the bedside should include auscultation, percussion and palpation for guarding, especially before discharging a flare patient overnight.

Laboratory investigations

• Stool calprotectin—primary triage in adults with chronic lower-GI symptoms when cancer is not suspected; high values (~≥150–250 µg/g) trigger gastroenterology referral.
• C. difficile stool testing—at every flare, before or alongside any escalation of immunosuppression.
• Complete blood count, CRP, ESR, electrolyte panel, urea/creatinine, liver function tests, albumin, ferritin and B12/folate to characterise inflammation, anaemia and nutritional status.
• Stool culture and parasite screen—exclude bacterial enteritis and parasitic alternatives.
• Pre-biologic screen—latent TB (IGRA + chest X-ray), hepatitis B serology (HBsAg, anti-HBc, anti-HBs), hepatitis C antibody, HIV when indicated, varicella history and an immunisation review.

Endoscopy and imaging

Ileocolonoscopy with biopsies from each segment (including normal-looking mucosa and the terminal ileum) is the diagnostic anchor. Upper GI endoscopy is added in suspected Crohn’s with upper-GI symptoms; capsule endoscopy and CT/MR enterography image small-bowel disease beyond the reach of standard scopes. MRI enterography (or pelvic MRI for perianal Crohn’s) is preferred when repeated imaging is anticipated, particularly in younger patients and in pregnancy. Intestinal ultrasound, where local expertise exists, is increasingly used to track disease activity without sedation.

1. Triage symptoms—chronic diarrhoea ± rectal bleeding, weight loss, abdominal pain >6 weeks: send fecal calprotectin and bloods; rule out cancer red flags (age >50 with new bowel change, family history, palpable mass, iron-deficiency anaemia).
2. Refer if calprotectin elevated or red flags—gastroenterology with planned ileocolonoscopy and biopsies; image small bowel as needed.
3. Confirm diagnosis—integrate clinical picture, biomarkers, endoscopic findings and histology; classify by Montreal extent and disease behaviour.
4. Treat to target—induce remission with appropriate first-line therapy; aim for symptomatic remission, then biomarker normalisation (CRP, calprotectin), then endoscopic improvement.
5. Step up if needed—biologics or small-molecule oral therapy for steroid-dependent, steroid-refractory or fistulating disease; complete pre-treatment safety screen first.
6. Maintain—right drug, right dose, drug-level monitoring where available, vaccinations up to date, planned surveillance scopes.
7. Escalate—any acute severe colitis, perforation, abscess, obstruction, massive bleed or new toxic colon goes urgently to gastroenterology + colorectal surgery; failure of rescue therapy means surgery, not more immunosuppression.

• Irritable bowel syndrome—chronic abdominal pain with altered bowel habit but normal calprotectin and inflammatory markers.
• Infectious colitis—Salmonella, Shigella, Campylobacter, E. coli O157, Yersinia, amoebiasis; sudden onset, exposure history, positive stool studies.
• Antibiotic-associated C. difficile infection—antibiotic exposure within 8 weeks; pseudomembranes on colonoscopy; toxin/PCR-positive stool.
• Diverticulitis—older patient, focal left-iliac-fossa pain, CT shows pericolic inflammation rather than continuous mucosal disease.
• Microscopic colitis—chronic watery diarrhoea, normal-looking mucosa endoscopically, lymphocytic or collagenous histology; common in older women on PPIs/NSAIDs.
• Ischaemic colitis—older, vascular comorbidity, watershed-segment pain and bleeding; CT and endoscopy distinguish.
• Celiac disease and small intestinal bacterial overgrowth—weight loss, anaemia, micronutrient deficits without colonic inflammation.
• Drug-induced colitis—NSAIDs, mycophenolate, immune-checkpoint inhibitors, gold compounds.
• Behçet’s disease, intestinal tuberculosis, intestinal lymphoma, sexually transmitted proctitis (LGV, syphilis, gonorrhoea, herpes)—important mimics in the right context.

↔On a small screen, swipe or scroll sideways to see the full table.

Induction (settle the flare) and maintenance (keep remission) are conceptually separate. Treatment is sequenced by phenotype, severity and response, anchored by the principle that long-term steroid use is a treatment failure rather than a maintenance plan.

Induction therapy

• Aminosalicylates (mesalamine)—first-line for mild–moderate UC (oral ± topical); limited benefit in Crohn’s disease.
• Topical therapy—rectal mesalamine (suppositories for proctitis, foam/enema for left-sided UC); often added to oral mesalamine for combined topical+oral effect.
• Corticosteroids—oral prednisolone tapered over ~8 weeks for moderate flares; budesonide (controlled-ileal-release or MMX) preferred where targeted action and lower systemic absorption matter; intravenous methylprednisolone or hydrocortisone for hospitalised severe flares.
• Antibiotics—metronidazole ± ciprofloxacin for perianal Crohn’s, fistulating disease and intra-abdominal sepsis; not used for routine flares.

Maintenance and steroid-sparing therapy

• Aminosalicylates for UC maintenance.
• Thiopurines (azathioprine, 6-mercaptopurine) and methotrexate as classical steroid-sparing immunomodulators—check TPMT/NUDT15 before starting thiopurines and monitor FBC/LFTs.
• Anti-TNF biologics—infliximab and adalimumab are first-line advanced therapy in moderate-to-severe Crohn’s and UC; combine with a thiopurine where appropriate to reduce immunogenicity.
• Anti-integrin biologics—vedolizumab is gut-selective with a favourable infection profile; effective in both UC and Crohn’s, particularly attractive in older patients or those with infection risk.
• Anti-IL-12/23 and anti-IL-23 biologics—ustekinumab (and newer anti-p19 agents such as risankizumab) are options across UC and Crohn’s, often after anti-TNF failure.
• Small-molecule oral therapy—Janus kinase inhibitors (tofacitinib, upadacitinib) and the sphingosine-1-phosphate modulator ozanimod for moderate-to-severe UC; cardiovascular, VTE and (with JAK inhibitors) malignancy/infection risks demand baseline screening and shared decision-making with older or higher-risk patients.
• Surgery—is not a failure of medical therapy but a parallel arm of management: ileocaecal resection for limited terminal-ileal Crohn’s, strictureplasty for short symptomatic strictures, panproctocolectomy with ileal pouch–anal anastomosis (IPAA) for refractory UC.

Special populations

• Pregnancy: aminosalicylates, thiopurines, anti-TNF and vedolizumab are generally continued; methotrexate is teratogenic and contraindicated; small-molecule oral agents are usually withheld unless no alternative exists. Plan delivery and infant vaccinations multidisciplinarily.
• Older adults: higher infection and VTE risks—favour gut-selective biologics where appropriate and co-manage cardiovascular risk before starting JAK inhibitors.
• Children: exclusive enteral nutrition is first-line induction in pediatric Crohn’s because of growth and steroid-sparing benefits; specialist paediatric IBD pathways apply.

Acute severe ulcerative colitis (ASUC) develops in roughly 15% of UC patients during their disease course and is one of the few true gastroenterology emergencies. The Truelove and Witts criteria define a severe flare as ≥6 bloody stools per day plus at least one systemic feature (temperature >37.8 °C, heart rate >90, haemoglobin <105 g/L, ESR >30 or CRP >30 mg/L). Management runs a tight, time-bound algorithm.

↔On a small screen, swipe or scroll sideways to see the full table.

Throughout admission, document daily stool charts (frequency, blood, urgency), maintain intake/output charts, weigh daily, monitor for VTE despite bleeding (low-molecular-weight heparin is appropriate unless bleeding is life-threatening), and avoid opioids and antimotility agents that mask deterioration and predispose to toxic megacolon.

Up to one-third of IBD patients develop extra-intestinal involvement at some point. Some manifestations parallel bowel activity and improve with luminal control; others run an independent course and may even drive treatment selection.

• Joints—peripheral arthritis (often parallels bowel activity) and axial spondyloarthritis (may co-exist with HLA-B27 and run independently); consider an ankylosing spondylitis overlap workup.
• Skin—erythema nodosum (parallels bowel activity), pyoderma gangrenosum (independent, painful necrotic ulcer), Sweet’s syndrome.
• Eyes—episcleritis (parallels activity), scleritis, anterior uveitis (acute red eye—same-day ophthalmology).
• Liver—primary sclerosing cholangitis affects ~5–8% of UC patients; check LFTs at every visit—particularly an unexplained ALP rise.
• Bones—steroid exposure and chronic inflammation drive osteoporosis; bone-density screening in steroid-exposed patients per local guidance.
• Kidney/stones—small-bowel Crohn’s predisposes to oxalate kidney stones; encourage hydration and dietary input where appropriate.
• Thrombosis—roughly threefold increase in deep vein thrombosis and pulmonary embolism during active disease and admission.

• Strictures and obstruction—particularly fibrotic Crohn’s; may need endoscopic dilatation or resection.
• Fistulae and abscesses—enteroenteric, enterovesical (faeculent urine, recurrent UTIs), enterocutaneous, perianal; need imaging and surgical input.
• Toxic megacolon and perforation—usually in severe flares.
• Lower GI bleeding—severe enough to require transfusion in a small subgroup.
• Colorectal cancer—elevated risk in long-standing colonic disease; mitigated by inflammation control and surveillance colonoscopy.
• Cholangiocarcinoma—linked with PSC overlap.
• Iron-deficiency and B12 anaemia—chronic blood loss, terminal-ileal disease/resection.
• Bone disease and growth failure—steroid-related and disease-related.
• Mental health—depression and anxiety are over-represented; ACG specifically endorses routine mental-health screening.

Primary prevention of IBD is not yet achievable, but secondary prevention—of flares, complications and treatment-related harm—is a defined ACG/BSG priority.

• Vaccination—annual influenza, age-appropriate pneumococcal, COVID-19 boosters, recombinant zoster (preferably before biologics), HPV per age, hepatitis A and B if non-immune. Avoid live vaccines on biologic or small-molecule therapy.
• Tobacco cessation—particularly important in Crohn’s disease.
• NSAID stewardship—document the recommendation and offer non-NSAID analgesia.
• Bone health—calcium and vitamin D, weight-bearing exercise, baseline DEXA in steroid-exposed patients per local guidance.
• Cancer surveillance—colonoscopy 8–10 years from symptom onset for colonic disease (annually if PSC), cervical cancer screening per national guidance, skin-cancer awareness particularly with thiopurines.
• Mental-health screening—routine depression and anxiety screening at IBD review, with onward referral pathways.
• VTE prophylaxis—LMWH for hospitalised patients during flares; mechanical prophylaxis when bleeding contraindicates anticoagulation.

IBD is a lifelong condition with a relapsing–remitting course. Most patients achieve sustained remission with modern therapy; those who reach early endoscopic healing have lower long-term colectomy and cancer rates than those who chase symptoms only. Roughly half of Crohn’s patients require a major resection within 10 years of diagnosis, and 10–20% of UC patients eventually undergo colectomy—often as a planned procedure rather than an emergency. Mortality rates approach those of the background population for most patients but rise with extensive long-standing disease, severe ASUC episodes, primary sclerosing cholangitis, IBD-related cancer and chronic high-dose steroid exposure. Quality-of-life improvements track most strongly with achieving and maintaining steroid-free deep remission.

• Treat “just a flare” as a working diagnosis until C. difficile, dietary triggers, NSAID use, and missed doses have been actively excluded.
• An admitted IBD patient who is not on prophylactic LMWH within 24 h of arrival is a missed safety opportunity—even when bleeding rectally—unless bleeding is life-threatening.
• A normal CRP does not exclude active small-bowel Crohn’s; some patients run a normal CRP throughout flares. Calprotectin and imaging carry the load instead.
• Listen to perianal complaints in young men—the diagnosis of fistulating Crohn’s is regularly delayed by months because patients (and clinicians) anchor on “haemorrhoids”.
• Pre-biologic checklists matter: latent TB and hepatitis B reactivation are preventable harms when the screen is done; missing them is a documented “never event” in many trusts.
• Stigma and body-image concerns are real—stoma counselling, sexual-health conversations and mental-health screening belong in routine review rather than at crisis points.

• Vitals + NEWS2—document baseline and trends with vital signs measurement; tachycardia and a creeping temperature precede overt deterioration.
• Stool chart—frequency, blood, urgency, formation; daily totals matter on day 3 of an ASUC admission.
• Pain trajectory—record severity and location with structured pain assessment; new constant or rebound pain prompts imaging.
• Hydration and weight—balance fluids, daily weight measurement, watch for “dry but ill” patients.
• Bedside labs—daily FBC, U&E, CRP, magnesium and phosphate; low albumin and rising platelets accompany severe flares.
• Stool collection—correct stool specimen collection on day 1 to capture C. difficile, culture and calprotectin.
• VTE prophylaxis—document LMWH prescription and TED stockings; record any contra-indication.
• Medication review—stop NSAIDs and antimotility agents; check biologic dosing schedule and last dose.
• Stoma/surgical readiness—pre-operative weight, marking, counselling and consent if surgery is on the table.

Red-flag symptom clusters

• Stool frequency rising despite IV steroids on day 2 of an ASUC admission.
• New abdominal distension, reduced bowel sounds and tenderness over the transverse colon.
• Persisting tachycardia >100, swinging temperature >38 °C or hypotension despite fluid resuscitation.
• Increasing analgesia requirements with new constant pain rather than crampy episodes.

Objective findings

• CRP >45 mg/L on day 3 of IV steroids, with stool frequency 3–8/day (Travis criteria for steroid failure).
• Plain abdominal film showing transverse colon dilatation >5.5–6 cm, mucosal islands or pneumatosis.
• Falling haemoglobin requiring transfusion, falling albumin <30 g/L, rising lactate.
• CT showing free gas, abscess, contained perforation, or wall thickening with stranding suggestive of severe colitis.

Escalation mechanics

• Ward: hourly observations during ASUC; nursing handover should explicitly flag the day-3 review point.
• Gastroenterology + colorectal surgery: joint review by day 3, mandatory if rescue therapy is being considered.
• Critical care: early involvement when fluid resuscitation, vasopressor need or pre-operative optimisation is anticipated.
• Sepsis pathway: trigger structured sepsis screening for any IBD patient with new fever, rigors, hypotension or perforation suspicion.

On admission

• Capture full IBD history—current and prior treatments, last flare, last colonoscopy, perianal symptoms, smoking status, family history.
• Confirm baseline labs and imaging are in place; chase fecal calprotectin, stool studies and inflammatory markers early.
• Set up IV access, prescribe LMWH prophylaxis, charts for stool, fluids and weight, and a documented day-3 review plan in ASUC.
• Reconcile medications with formal medication reconciliation—stop NSAIDs and antimotility agents; flag any biologic doses due during admission.

During admission

• Run a sustained hand hygiene and contact-precautions discipline if C. difficile is suspected; consider isolation precautions per local policy.
• Coordinate stoma counselling and pre-operative marking before urgent colectomy so the patient is familiar with stoma siting and equipment before theatre.
• Maintain accurate intake-output charting and daily weights; deterioration is often quiet in young patients with good physiologic reserve.
• Document and act on extra-intestinal symptoms—new red eye, joint swelling or skin ulcer—rather than parking them under “chronic disease”.

Discharge and follow-up

• Plain-language steroid taper plan, biologic injection technique check, and clear sick-day rules (when to stop NSAIDs, when to come back, who to call).
• Confirm vaccination status, calcium/vitamin D, smoking-cessation referral and contraception/pregnancy planning where relevant.
• Schedule the planned outpatient calprotectin, drug-level review, surveillance colonoscopy or biologic infusion before discharge—not after.
• Signpost mental-health resources, IBD-specialist nurse contact, and relevant patient organisations.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a cloze drop-down on the topic of the day-3 ASUC pathway, biologic safety screening, fecal calprotectin triage and recognition of toxic colon—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action in the acute IBD patient.